Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $485 price target.
Cantor Fitzgerald maintained Eli Lilly (NYSE:LLY) $485 price target Read Post »
AbbVie(NYSE:ABBV) reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year earlier. Analysts polled by Capital IQ expected $2.48. Net revenue for the quarter ended March 31 was $12.23 billion, compared with $13.54 billion a year earlier. Analysts surveyed by Capital IQ expected $12.25 billion. The company raised its adjusted earnings guidance for full-year 2023 to $10.72 to $11.12 per diluted share from $10.62 to $11.02. Analysts polled by Capital IQ expect 2023 adjusted earnings of $10.95.
AbbVie (NYSE:ABBV) Raised 2023 Adjusted Earnings Guidance Read Post »
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $200 to $195.
Wells Fargo lowered AbbVie (NYSE:ABBV) price target from $200 to $195 Read Post »
Piper Sandler analyst Joseph Catanzaro assumes Gilead Sciences (NASDAQ:GILD) with a Overweight rating and announces Price Target of $105.
Piper Sandler announced Gilead Sciences (NASDAQ:GILD) Price Target of $105 Read Post »
Boston Scientific (NYSE:BSX) Raises 2023 Adj. EPS Outlook to $1.90-$1.96 From $1.86-$1.93; Boston Scientific (NYSE:BSX) Sees 2Q Sales Up 6.5%-8.5%, Organic Sales Up 7%-9%
Needham analyst Mike Matson maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $56 to $57.
Needham raised Boston Scientific (NYSE:BSX) price target from $56 to $57 Read Post »
Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $52 to $58.
Stifel raised Boston Scientific (NYSE:BSX) price target from $52 to $58 Read Post »
Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $292 to $290.
Oppenheimer lowered Amgen (NASDAQ:AMGN) price target from $292 to $290 Read Post »
Amgen (NASDAQ:AMGN) said it expects full-year 2023 non-GAAP diluted earnings of $17.60 to $18.70, up from the previous guidance of $17.40 to $18.60. Analysts surveyed by Capital IQ expect $17.86. The company expects revenue for the year of $26.2 billion to $27.3 billion, up from the previous guidance of $26.0 billion to $27.2 billion. Analysts surveyed by Capital IQ expect $28.72 billion.
Amgen (NASDAQ:AMGN) Raised 2023 Guidance Read Post »
The biotechnology company guided for revenue between $26.2 billion and $27.3 billion, earnings per share of $15.38 to $16.59 and adjusted earnings between $17.60 and $18.70 a share. Amgen previously forecast revenue of $26 billion to $27.2 billion, earnings per share between $13.16 and $14.41, and adjusted earnings of $17.40 to $18.60 a share. The company said its outlook excludes any contribution from its acquisition of Horizon Therapeutics PLC, which is expected to close in the first half of 2023. Chief Executive Robert Bradway said demand for its products globally resulted in 14% volume growth in the first quarter.
Amgen(NASDAQ:AMGN) Raises 2023 Revenue, EPS Outlook Read Post »
Gilead Sciences (NASDAQ:GILD) provid For 2023, Gilead retains non-GAAP diluted EPS of between $6.60 and $7 on total product sales between $26 billion and $26.5 billion, both unchanged from the previous guidance. Analysts polled by Capital IQ expected a normalized EPS of $6.84 on revenue of $26.73 billion.
Gilead Sciences (NASDAQ:GILD) Retains 2023 Guidance Read Post »
RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:GILD) with a Sector Perform and maintains $87 price target.
RBC Capital maintained Gilead Sciences (NASDAQ:GILD) $87 price target Read Post »